P-0208 - Combination of Oxaliplatin + Fluorouracil compared to Fluoropyrimidine single Agent in adjuvant treatment of Young patients with Colon cancer

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Cancer in Young Adults
Colon Cancer
Presenter Mohammed Shahin
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors M. Shahin1, N. Abbas2, R. Abdelmalek1, E. El Gonimy3
  • 1Cairo Oncology Centre, Giza/EG
  • 2Cairocure Oncology Center, Giza/EG
  • 3Kasr El Ainy, Cairo/EG



Colon cancer in young individuals is increasingly common problem in Egypt with more aggressive disease and worse 5-years survival compared to their older counterpart. Thus we carried a retrospective analysis for patients with colon cancer who received Adjuvant therapy aiming to evaluate the magnitude of benefit adding Oxaliplatin to Fluoropyrimidine-based chemotherapy according to patient's age.


We retrospectively identified patients with colon cancer presenting to Kasr al-ainy oncology center in period between January 2009 – Decemer 2013 who were candidate for adjuvant chemotherapy. Files were reviewed for patient's age, gender, pathological subtype, grade, stage, type of chemotherapy received date and site of relapse. All data were tabulated and statistically studied by descriptive analysis as well as survival analysis in relation to different prognostic factors. Comparison between groups was done using Student t test for continuous data and Chi square test for categorical data. Survival analysis was done according to Kaplan-Meier method and compared by log-rank test for significance.


One hundred forty patients were included in our analysis of which 55 patients were less than 40 years old, 29 were males (53%) and 26 females (47%). Thirty four patients were treated with combination of oxaliplatin and fluorouracil, and 21 patients received single agent fluorouracil. The Median overall survival (OS) was 43 months, five years disease free survival (DFS) was 37%. Using multivariate analysis, factors significantly affecting overall survival were gender (p= 0.001), Stage (p= 0.002) and combination of oxaliplatin and fluorouracil (p= 0.001). The magnitude of benefit from combination chemotherapy was more significant in patients younger than 40 years compared to those older than 40 years.


According to our study, adding Oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy significantly improves overall survival especially in patients younger than 40 years of age.